

## СПИСОК ЛИТЕРАТУРЫ

1. *Coates A. R., Hu Y.* Novel approaches to developing new antibiotics for bacterial infections. *Br J Pharmacol.* 2007; 152(8):1147-54.
2. *Fleming A.* Discussion on Vaccine Therapy: its Treatment, Value, and Limitations. *Proc R Soc Med.* 1910; 3 (Gen Rep):137-9.
3. *Adami J. G., Bowman F. B., Adams F., Fleming A. G., Farquharson C. D., Imrie C., et al.* Combined Inquiry into the Presence of Diphtheria and Diphtheroid Bacilli in Open Wounds. *Can Med Assoc J.* 1918;8(9):769-85.
4. *Munroe A. R., Fleming A. G., Janes R. M.* Wound flora in relation to secondary suture. *Br Med J.* 1918;1(2980):173.
5. *Fleming A.* A British Medical Association Lecture on vaccine therapy in regard to general practice. *Br Med J.* 1921;1(3138):255-9.
6. *Fleming A.* The Bactericidal Power of Human Blood and some Methods of Altering It. *Proc R Soc Med.* 1928;21(5):859-68.
7. *Fleming A.* Lysozyme: President's Address. *Proc R Soc Med.* 1932;26(2):71-84.
8. *Fleming A.* The assay of penicillin in the days before it was concentrated. *Health Organ Bull.* 1945;12(2):250-2.
9. *Fleming A.* Antiseptics, old and new. *Proc Staff Meet Mayo Clin.* 1946;21:67-75.
10. *Fleming A.* The development and use of penicillin. *Chic Med Sch Q.* 1946;7(2):20-8.
11. *Fleming A., Smith C.* Estimation of penicillin in serum; use of glucose, phenol red, and serum water. *Lancet.* 1947;1(6448):401.

12. *Fleming A., Walters W.* Penicillin in surgery. *Lancet*. 1947;2(6474):479.
13. *Fleming A.* Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae* by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. *Rev Infect Dis*. 1980;2(1):129-39.
14. *Morphy A. G.* Thoughts by a physician on the battle of the marne. *Can Med Assoc J*. 1927;17(7):848.
15. *Cuvier G.* [Pathology of the german generals at the battle of the marne]. *Presse Med*. 1964;72:2119-20.
16. *Boyd J.* Tetanus in two world wars. *Proc R Soc Med*. 1959;52(2):109-10.
17. *Wever P. C., van Bergen L.* Prevention of tetanus during the First World War. *Med Humanit*. 2012;38(2):78-82.
18. *Colebrook L.* Almroth Wright; pioneer in immunology. *Br Med J*. 1953;2(4837):635-40.
19. *Allison V. D.* Personal recollections of Sir Almroth Wright and Sir Alexander Fleming. *Ulster Med J*. 1974; 43(2):89-98.
20. *IVY R. H.* The influenza epidemic of 1918. Personal experience of a medical officer in World War I. *Mil Med*. 1960; 125:620-2.
21. *Robinson K. R.* The role of nursing in the influenza epidemic of 1918–1919. *Nurs Forum*. 1990; 25(2):19-26.
22. *Aminov R. I.* A brief history of the antibiotic era: lessons learned and challenges for the future. *Front Microbiol*. 2010; 1:134.
23. *Ioset J. R., Kaur H.* Simple field assays to check quality of current artemisinin-based antimalarial combination formulations. *PLoS One*. 2009; 4(9):e7270.
24. *Yoshida T., Nasu H., Yamashita M.* Construction of the control system of target molecule expression in *Escherichia coli*: application to a validation platform for bactericidal and bacteriostatic

- profiles due to suppression of a target molecule. *FEMS Microbiol Lett.* 2012;331(2):113-9.
25. *Vinson C. G.* Possible chemical nature of tobacco mosaic virus. *Science.* 1934;79(2059):548-9.
  26. *Stanley W. M.* The inactivation of crystalline tobacco-mosaic virus protein. *Science.* 1936;83(2165):626-7.
  27. *Hey S. P., Kesselheim A. S.* Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. *Hastings Cent Rep.* 2017;47(2):16-20.
  28. *Lobanovska M., Pilla G.* Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future? *Yale J Biol Med.* 2017;90(1):135-45.
  29. *Luepke K. H., Suda K. J., Boucher H., Russo R. L., Bonney M. W., Hunt T. D., et al.* Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. *Pharmacotherapy.* 2017;37(1):71-84.
  30. *Finland M., Weinstein L.* Complications induced by antimicrobial agents. *N Engl J Med.* 1953;248(6):220-6.
  31. *Johnston A. W.* Aplastic anaemia following treatment with chloramphenicol: transfusion of polycythaemic blood using sequestrene. *Lancet.* 1954;267(6833):319.
  32. *Dameshek W.* Chloramphenicol--a new warning. *JAMA.* 1960;174:1853-4.
  33. *Fleischmann R. D., Adams M. D., White O., Clayton R. A., Kirkness E. F., Kerlavage A. R., et al.* Whole-genome random sequencing and assembly of *Haemophilus influenzae* Rd. *Science.* 1995;269(5223):496-512.
  34. *Tse B. N., Adalja A. A., Houchens C., Larsen J., Inglesby T. V., Hatchett R.* Challenges and Opportunities of Nontraditional Approach-

- es to Treating Bacterial Infections. *Clin Infect Dis*. 2017;65(3):495-500.
35. *Svennebring A. M., Wikberg J. E.* Net present value approaches for drug discovery. *Springerplus*. 2013;2(1):140.
  36. *Stachelhaus T., Schneider A., Marahiel M. A.* Rational design of peptide antibiotics by targeted replacement of bacterial and fungal domains. *Science*. 1995;269(5220):69-72.
  37. *Ma Q. Q., Lv Y. F., Gu Y., Dong N., Li DS, Shan A. S.* Rational design of cationic antimicrobial peptides by the tandem of leucine-rich repeat. *Amino Acids*. 2013;44(4):1215-24.
  38. *Boucher H. W., Talbot G. H., Dunne M. W.* Dalbavancin or oritavancin for skin infections. *N Engl J Med*. 2014;371(12):1161-2.
  39. *Bernareggi A., Danese A., Cavenaghi L.* Pharmacokinetics of A40926 in rats after single intravenous and subcutaneous doses. *Antimicrob Agents Chemother*. 1988;32(2):246-9.
  40. *Marcone G. L., Beltrametti F., Binda E., Carrano L., Foulston L., Hesketh A., et al.* Novel mechanism of glycopeptide resistance in the A40926 producer *Nonomurea* sp. ATCC 39727. *Antimicrob Agents Chemother*. 2010;54(6):2465-72.
  41. *Steiert M., Schmitz F. J.* Dalbavancin (Biosearch Italia/Versicor). *Curr Opin Investig Drugs*. 2002;3(2):229-33.
  42. *Bosso J. A.* The antimicrobial armamentarium: evaluating current and future treatment options. *Pharmacotherapy*. 2005;25(10 Pt 2):55S-62S.
  43. *Domagk G.* Twenty-five years of sulfonamide therapy. *Ann N Y Acad Sci*. 1957;69(3):380-4.
  44. *A G N.* The Elixir Sulfanilamide-Massengill. *Can Med Assoc J*. 1937;37(6):590.
  45. *Gay F. P., Clark A. R.* On the mode of action of sulfanilamide in experimental streptococcus empyema. *J Exp Med*. 1937;66(5):535-48.

46. Geiger J. C. Concerning Elixir of Sulfanilamide. *Cal West Med.* 1937;47(5):353.
47. Locke A., Locke R. B., Bragdon R. J., Mellon R. R. Fitness, sulfanilamide and pneumococcus infection in the rabbit. *Science.* 1937;86(2227):228-9.
48. Finkelstein R., Birkeland J. M. The mode of action of sulfanilamide and prontosil. *Science.* 1938;87(2263):441-2.
49. Hanigan W. C. Neurological surgery during the Great War: the influence of Colonel Cushing. *Neurosurgery.* 1988;23(3):283-94.
50. Domagk G. *Br Med J.* 1964;1(5391):1189.
51. Raju T. N. The Nobel chronicles. 1939: Gerhard Domagk (1895-1964). *Lancet.* 1999;353(9153):681.
52. Boozer J. S. Children of Hippocrates: doctors in Nazi Germany. *Ann Am Acad Pol Soc Sci.* 1980(450):83-97.
53. Levine C. What's in a name? The Eppinger Prize and Nazi experiments. *Hastings Cent Rep.* 1984;14(6):3-4.
54. Kevorkian J. A brief history of experimentation on condemned and executed humans. *J Natl Med Assoc.* 1985;77(3):215-26.
55. Shuster E. American Doctors at the Nuremberg Medical Trial. *Am J Public Health.* 2018;108(1):47-52.
56. Harkness J. M. Nuremberg and the issue of wartime experiments on US prisoners. The Green Committee. *JAMA.* 1996;276(20):1672-5.
57. Adashi E. Y., Walters L. B., Menikoff J. A. The Belmont Report at 40: Reckoning With Time. *Am J Public Health.* 2018; 108(10):1345-8.
58. Merz J. F. The Nuremberg Code and Informed Consent for Research. *JAMA.* 2018;319(1):85-6.
59. Vonderlehr R. A. Increasing Opportunities for the Clinician in Public Health Work. *J Natl Med Assoc.* 1940;32(3):93-6.

60. *Vonderlehr R. A.* Concerning the fight against syphilis. *Cal West Med.* 1937;46(3):202.
61. *Curran W. J.* The tuskegee syphilis study. *N Engl J Med.* 1973;289(14):730-1.
62. *White R. M.* Unraveling the Tuskegee Study of Untreated Syphilis. *Arch Intern Med.* 2000;160(5):585-98.
63. *Hill W. R.* Problems arising in the treatment of syphilis with penicillin. *N Engl J Med.* 1946;235(26):919-24.
64. *Barker W. F.* Syphilitic aortitis with obstruction of multiple aortic ostia. *N Engl J Med.* 1949;241(14):524-7.
65. *Heyman A., McCain J. R.* Syphilis in pregnancy; a clinical study of factors responsible for congenital syphilis. *N Engl J Med.* 1949;241(24):960-4.
66. *Brandt A. M.* Racism and research: the case of the Tuskegee Syphilis Study. *Hastings Cent Rep.* 1978;8(6):21-9.
67. *Beecher H. K.* Ethics and clinical research. *N Engl J Med.* 1966;274(24):1354-60.
68. *Welch C. E., Henry K., Beecher M. D.* *N Engl J Med.* 1976;295(13):730.
69. *Rothman D. J.* Ethics and human experimentation. Henry Beecher revisited. *N Engl J Med.* 1987;317(19):1195-9.
70. *Jones D. S., Grady C., Lederer S. E.* "Ethics and Clinical Research" — The 50th Anniversary of Beecher's Bombshell. *N Engl J Med.* 2016;374(24):2393-8.
71. *Laurent J.* Milgram's shocking experiments; a case in the social construction of 'science'. *Indian J Hist Sci.* 1987;22(3):247-72.
72. *Gibson S.* Obedience without orders: Expanding social psychology's conception of 'obedience'. *Br J Soc Psychol.* 2018.
73. *Benedetti F.* Beecher as Clinical Investigator: Pain and the Placebo Effect. *Perspect Biol Med.* 2016;59(1):37-45.

74. *Senate USC.* (Reprint of) National Research Act. Conference Report. Drug Res Rep. 1974;17(28):51-536.
75. *Finlay K. A., Fernandez C. V.* Failure to report and provide commentary on research ethics board approval and informed consent in medical journals. J Med Ethics. 2008;34(10):761-4.
76. *Levine R. J., Lasagna L.* Demystifying central review boards: current options and future directions. IRB. 2000;22(6):1-9.
77. *Edgar H., Rothman D. J.* The institutional review board and beyond: future challenges to the ethics of human experimentation. Milbank Q. 1995;73(4):489-506.
78. *Quinn K.* After the revolution: DRGs at age 30. Ann Intern Med. 2014;160(6):426-9.
79. *Blum M. D., Graham D. J., McCloskey C. A.* Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994;18(6):946-50.
80. *Guillard T., Pons S., Roux D., Pier G. B., Skurnik D.* Antibiotic resistance and virulence: Understanding the link and its consequences for prophylaxis and therapy. Bioessays. 2016;38(7):682-93.
81. *Skurnik D., Roux D., Pons S., Guillard T., Lu X., Cywes-Bentley C., et al.* Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71(4):927-35.
82. *Spellberg B., Bartlett J. G., Gilbert D. N.* The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299-302.
83. *Jawetz E.* Antimicrobial chemotherapy. Annu Rev Microbiol. 1956;10:85-114.
84. *Corrigan-Curay J., McKee A. E., Stein P.* Breakthrough-Therapy Designation — An FDA Perspective. N Engl J Med. 2018;378(15):1457-8.
85. *Woloshin S., Schwartz L. M., White B., Moore T. J.* The Fate of FDA Postapproval Studies. N Engl J Med. 2017;377(12):1114-7.

86. *Gellad W. F., Kesselheim A. S.* Accelerated Approval and Expensive Drugs — A Challenging Combination. *N Engl J Med.* 2017;376(21):2001-4.
87. *Resnic F. S., Matheny M. E.* Medical Devices in the Real World. *N Engl J Med.* 2018;378(7):595-7.
88. *Hudson A., Lopez E., Almalki A. J., Roe A. L., Calderón A. I.* A Review of the Toxicity of Compounds Found in Herbal Dietary Supplements. *Planta Med.* 2018;84(9-10):613-26.
89. *Salinas E.* Access to Essential Medicines in the United States. *N Engl J Med.* 2016;375(9):904.
90. *Ivanovska V., Leufkens H. G., Rademaker C. M., Zisovska E., Pijnenburg M. W., van Dijk L., et al.* Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study. *Arch Dis Child.* 2017;102(4):352-6.
91. *Puthumana J., Wallach J. D., Ross J. S.* Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation. *JAMA.* 2018;320(3):301-3.
92. *Valiquette L., Laupland K. B.* Antimicrobial shortages: Another hurdle for clinicians. *Can J Infect Dis Med Microbiol.* 2015; 26(2):67-8.
93. *McLaughlin M. M., Skoglund E., Pentoney Z., Scheetz M. H.* Developing a Method for Reporting Patient Harm Due to Antimicrobial Shortages. *Infect Dis Ther.* 2014;3(2):349-55.
94. *Gilbert D. N., Edwards J. E.* Is there hope for the prevention of future antimicrobial shortages? *Clin Infect Dis.* 2002;35(2):215-6; author reply 6-7.
95. *Kessel J., Dolff B., Wichelhaus T., Keiner N., Hogardt M., Reinheimer C., et al.* [Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital]. *Dtsch Med Wochenschr.* 2018;143(8):e59-e67.



96. *Nurse-Findlay S., Taylor M. M., Savage M., Mello M. B., Saliyou S., Lavayen M., et al.* Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews. *PLoS Med.* 2017;14(12):e1002473.
97. *Watkins D. A., Johnson C. O., Colquhoun S. M., Karthikeyan G., Beaton A., Bukhman G., et al.* Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. *N Engl J Med.* 2017;377(8):713-22.
98. *Mensah G. A., Roth G. A., Sampson U. K., Moran A. E., Feigin V. L., Forouzanfar M. H., et al.* Mortality from cardiovascular diseases in sub-Saharan Africa, 1990-2013: a systematic analysis of data from the Global Burden of Disease Study 2013. *Cardiovasc J Afr.* 2015;26(2 Suppl 1):S6-10.
99. *Boucher H. W., Ambrose P. G., Chambers H. F., Ebright R. H., Jezek A., Murray B. E., et al.* White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs. *J Infect Dis.* 2017;216(2):228-36.
100. *Bloom G., Merrett G. B., Wilkinson A., Lin V., Paulin S.* Antimicrobial resistance and universal health coverage. *BMJ Glob Health.* 2017;2(4):e000518.
101. *Lowy F. D.* How *Staphylococcus aureus* adapts to its host. *N Engl J Med.* 2011;364(21):1987-90.
102. *Lowy F. D.* Mapping the distribution of invasive *Staphylococcus aureus* across Europe. *PLoS Med.* 2010;7(1):e1000205.
103. *Dyer O.* Allergan transfers Restasis patent to Mohawk tribe to deter challenges from generics. *BMJ.* 2017;358:j4280.
104. *Gavril D., Woerther P. L., Ben Lakhdar A., Mahjoubi L., Routier E., Chachaty E., et al.* Invasive cutaneous infection due to *Sco-pulariopsis brevicaulis* unsuccessfully treated with high-dose micafungin in a neutropenic patient. *Infection.* 2017;45(3):361-3.

105. *Hazen E. L., Brown R.* Nystatin. *Ann N Y Acad Sci.* 1960;89:258-66.
106. *Brown R., Hazen E. L.* Present knowledge of nystatin, an anti-fungal antibiotic. *Trans N Y Acad Sci.* 1957;19(5):447-56.
107. *Brown R., Hazen E. L., Mason A.* Effect of fungicidin (nystatin) in mice injected with lethal mixtures of aureomycin and *Candida albicans*. *Science.* 1953;117(3048):609-10.
108. *Hazen E. L., Brown R., Mason A.* Protective action of fungicidin (nystatin) in mice against virulence enhancing activity of oxy-tetracycline on *Candida albicans*. *Antibiot Chemother (Northfield).* 1953;3(11):1125-8.
109. *Hazen E. L., Brown R.* Fungicidin, an antibiotic produced by a soil actinomycete. *Proc Soc Exp Biol Med.* 1951;76(1):93-7.
110. *Årdal C., Baraldi E., Theuretzbacher U., Outtersson K., Plahte J., Ciabuschi F., et al.* Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. *J Pharm Policy Pract.* 2018;11:8.
111. *Baraldi E., Lindahl O., Savic M., Findlay D., Årdal C.* Antibiotic Pipeline Coordinators. *J Law Med Ethics.* 2018;46(1\_suppl):25-31.
112. *Savic M, Årdal C. A.* Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics. *J Law Med Ethics.* 2018;46(1\_suppl):9-24.
113. *Storehagen L., Aftab F., Årdal C., Savic M., Røttingen J.A.* Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug Regimen. *J Law Med Ethics.* 2018;46(1\_suppl):81-94.
114. *Årdal C., Røttingen J. A.* Open source drug discovery in practice: a case study. *PLoS Negl Trop Dis.* 2012;6(9):e1827.
115. *Blum R., Stanton G. H., Sagi S., Richter E. D.* 'Ethnic cleansing' bleaches the atrocities of genocide. *Eur J Public Health.* 2008;18(2):204-9.

116. *Kellermann N. P.* Epigenetic transmission of Holocaust trauma: can nightmares be inherited? *Isr J Psychiatry Relat Sci.* 2013;50(1):33-9.
117. *Yehuda R., Lehrner A., Bierer L. M.* The public reception of putative epigenetic mechanisms in the transgenerational effects of trauma. *Environ Epigenet.* 2018;4(2):dvy018.
118. *Yehuda R., Daskalakis N. P., Bierer L. M., Bader H. N., Klengel T., Holsboer F., et al.* Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation. *Biol Psychiatry.* 2016;80(5):372-80.
119. *DiDiodato G., Fruchter L.* Antibiotic exposure and risk of community-associated *Clostridium difficile* infection: A self-controlled case series analysis. *Am J Infect Control.* 2018.
120. *Lowe C. F., Payne M., Puddicombe D., Mah A., Wong D., Kirkwood A., et al.* Antimicrobial stewardship for hospitalized patients with viral respiratory tract infections. *Am J Infect Control.* 2017.
121. *Griffith R. S.* Introduction to vancomycin. *Rev Infect Dis.* 1981;3 suppl:S200-4.
122. *Griffith R. S.* Vancomycin use--an historical review. *J Antimicrob Chemother.* 1984;14 Suppl D:1-5.
123. *Darko W., Medicis J. J., Smith A., Guharoy R., Lehmann D. E.* Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. *Pharmacotherapy.* 2003;23(5):643-50.
124. *Elting L. S., Rubenstein E. B., Kurtin D., Rolston K. V., Fangtang J., Martin C. G., et al.* Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. *Cancer.* 1998;83(12):2597-607.
125. *London A. J.* Social value, clinical equipoise, and research in a public health emergency. *Bioethics.* 2018.

126. *Cunney K. A., Miller H. W.* Participation in clinical drug studies: motivations and barriers. *Clin Ther.* 1994;16(2):273-82; discussion 1-2.
127. *Chen S. C., Sinaii N., Bedarida G., Gregorio M. A., Emanuel E., Grady C.* Phase 1 healthy volunteer willingness to participate and enrollment preferences. *Clin Trials.* 2017;14(5):537-46.
128. *Grady C., Bedarida G., Sinaii N., Gregorio M. A., Emanuel E. J.* Motivations, enrollment decisions, and socio-demographic characteristics of healthy volunteers in phase 1 research. *Clin Trials.* 2017;14(5):526-36.
129. *Comerci G., Katzman J., Duhigg D.* Controlling the Swing of the Opioid Pendulum. *N Engl J Med.* 2018;378(8):691-3.
130. Opiate deaths demand serious action. *Nature.* 2017; 551(7682):541-2.
131. *Salamone F. R.* Clinical pharmacology of antibiotics. Sulbactam/ampicillin. *Infect Control Hosp Epidemiol.* 1988;9(7):323-7.
132. Centers for Disease Control and Prevention HHS. World Trade Center Health Program; addition of certain types of cancer to the list of WTC-related health conditions. Final rule. *Fed Regist.* 2012;77(177):56138-68.
133. *Durán Graeff L., Seidel D., Vehreschild M. J., Hamprecht A., Kindo A., Racil Z., et al.* Invasive infections due to *Saprochaete* and *Geotrichum* species: Report of 23 cases from the FungiScope Registry. *Mycoses.* 2017;60(4):273-9.
134. *Vaux S., Criscuolo A., Desnos-Ollivier M., Diancourt L., Tarnaud C., Vandenberghe M., et al.* Multicenter outbreak of infections by *Saprochaete clavata*, an unrecognized opportunistic fungal pathogen. *MBio.* 2014;5(6).
135. *Kontoyiannis D. P., Perlin D. S., Roilides E., Walsh T. J.* What can we learn and what do we need to know amidst the iatrogenic

- outbreak of *Exserohilum rostratum* meningitis? *Clin Infect Dis*. 2013;57(6):853-9.
136. *McCarthy M., Rosengart A., Schuetz A. N., Kontoyiannis D. P., Walsh T.J.* Mold infections of the central nervous system. *N Engl J Med*. 2014;371(2):150-60.
137. *Montgomery M. P., Robertson S., Koski L., Salehi E., Stevenson L. M., Silver R., et al.* Multidrug-Resistant *Campylobacter jejuni* Outbreak Linked to Puppy Exposure - United States, 2016-2018. *MMWR Morb Mortal Wkly Rep*. 2018;67(37):1032-5.
138. *Ström G., Boqvist S., Albihn A., Fernström L. L., Andersson Djurfeldt A., Sokerya S., et al.* Antimicrobials in small-scale urban pig farming in a lower middle-income country - arbitrary use and high resistance levels. *Antimicrob Resist Infect Control*. 2018;7:35.
139. *Abdel-Wahab N., Shah M., Suarez-Almazor M. E.* Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. *PLoS One*. 2016;11(7):e0160221.
140. *Gajewski T. F.* Fast Forward - Neoadjuvant Cancer Immunotherapy. *N Engl J Med*. 2018;378(21):2034-5.
141. *Garon E. B.* Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. *N Engl J Med*. 2017;376(25):2483-5.
142. *Caliendo A. M., Hodinka R. L.* A CRISPR Way to Diagnose Infectious Diseases. *N Engl J Med*. 2017;377(17):1685-7.
143. *Graham D. B., Root D. E.* Resources for the design of CRISPR gene editing experiments. *Genome Biol*. 2015;16:260.
144. *Reardon S.* Modified viruses deliver death to antibiotic-resistant bacteria. *Nature*. 2017;546(7660):586-7.
145. *Kumarasamy K. K., Toleman M. A., Walsh T. R., Bagaria J., Butt F., Balakrishnan R., et al.* Emergence of a new antibiotic resistance

- mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis.* 2010;10(9):597-602.
146. *Marra A.* NDM-1: a local clone emerges with worldwide aspirations. *Future Microbiol.* 2011;6(2):137-41.
  147. *Sepkowitz K. A.* Finland, Weinstein, and the birth of antibiotic regret. *N Engl J Med.* 2012;367(2):102-3.
  148. *Wring S. A., Randolph R., Park S, Abruzzo G., Chen Q., Flattery A., et al.* SCY-078 A First in Class Orally Active Antifungal Glucan Synthesis Inhibitor: Pre-Clinical Pharmacokinetics and Pharmacodynamic Target in Murine Models of Disseminated Candidiasis. *Antimicrob Agents Chemother.* 2017.
  149. *Satoh K., Makimura K., Hasumi Y., Nishiyama Y., Uchida K., Yamaguchi H.* *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol.* 2009;53(1):41-4.
  150. *Veve M. P., Wagner J. L.* Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. *Pharmacotherapy.* 2018; 38(9):935-46.
  151. *Lomovskaya O., Sun D., Rubio-Aparicio D., Nelson K., Tsivkovski R., Griffith D. C., et al.* Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. *Antimicrob Agents Chemother.* 2017.
  152. *Ito A., Nishikawa T., Matsumoto S., Yoshizawa H., Sato T., Nakamura R., et al.* Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2016;60(12):7396-401.
  153. *Flexner S., Jobling J. W.* An analysis of four hundred cases of epidemic meningitis treated with the anti-meningitis serum. *J Exp Med.* 1908;10(5):690-733.

154. *Schuch R., Nelson D., Fischetti V. A.* A bacteriolytic agent that detects and kills *Bacillus anthracis*. *Nature*. 2002;418(6900):884-9.
155. *Fischetti V. A., Gotschlich E. C., Bernheimer A. W.* Purification and physical properties of group C streptococcal phage-associated lysin. *J Exp Med*. 1971;133(5):1105-17.
156. *Bush L. M., Abrams B. H., Beall A., Johnson C. C.* Index case of fatal inhalational anthrax due to bioterrorism in the United States. *N Engl J Med*. 2001;345(22):1607-10.
157. *Revich B., Tokarevich N., Parkinson A. J.* Climate change and zoonotic infections in the Russian Arctic. *Int J Circumpolar Health*. 2012;71:18792.
158. *Slocum AMY.* A surgeon's nightmare: pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis. *BMJ Case Rep*. 2017;2017.
159. *Cameron D. J.* An appraisal of "chronic Lyme disease". *N Engl J Med*. 2008;358(4):429-30; author reply 30-1.
160. *Drapkin M. S.* An appraisal of "chronic Lyme disease". *N Engl J Med*. 2008;358(4):430; author reply -1.
161. *Feder H. M., Johnson B. J., O'Connell S., Shapiro E. D., Steere A. C., Wormser G. P., et al.* A critical appraisal of "chronic Lyme disease". *N Engl J Med*. 2007;357(14):1422-30.
162. *Donta S. T.* Treatment of patients with persistent symptoms and a history of Lyme disease. *N Engl J Med*. 2001;345(19):1424; author reply 5.
163. *Simon M. A., Haring R., Rodriguez E. M., González E., Kaur J. S., Kirschner M., et al.* Improving Research Literacy in Diverse Minority Populations with a Novel Communication Tool. *J Cancer Educ*. 2018.
164. *Tahhan A. S., Vaduganathan M., Greene S. J., Fonarow G. C., Fiu-zat M., Jessup M., et al.* Enrollment of Older Patients, Women,

- and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. *JAMA Cardiol.* 2018.
165. *Virgili A., Zampino M. R., Mantovani L.* Fungal skin infections in organ transplant recipients. *Am J Clin Dermatol.* 2002;3(1):19-35.
  166. *Hammarlöf D. L., Kröger C., Owen S. V., Canals R., Lacharme-Lora L., Wenner N., et al.* Role of a single noncoding nucleotide in the evolution of an epidemic African clade of. *Proc Natl Acad Sci U S A.* 2018;115(11):E2614-E23.
  167. *Small K. W., Chan C. K., Silva-Garcia R., Walsh T. J.* Onset of an outbreak of *Bipolaris hawaiiensis* fungal endophthalmitis after intravitreal injections of triamcinolone. *Ophthalmology.* 2014;121(4):952-8.
  168. *Foolad F., Taylor B. D., Shelburne S. A., Arias C. A., Aitken S. L.* Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. *J Antimicrob Chemother.* 2018;73(9):2277-83.
  169. *Mylonakis E., Clancy C. J., Ostrosky-Zeichner L., Garey K. W., Alangaden G. J., Vazquez J. A., et al.* T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clin Infect Dis.* 2015;60(6):892-9.
  170. *Hover B. M., Kim S. H., Katz M., Charlop-Powers Z., Owen J. G., Ternei M. A., et al.* Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. *Nat Microbiol.* 2018;3(4):415-22.
  171. *Relman A. S.* What you always wanted to know about the Howard Hughes Medical Institute but were afraid to ask. *N Engl J Med.* 1978;299(23):1303-5.
  172. *Nichols D., Cahoon N., Trakhtenberg E. M., Pham L., Mehta A., Belanger A., et al.* Use of ichip for high-throughput in situ cul-



- tivation of “uncultivable” microbial species. *Appl Environ Microbiol.* 2010;76(8):2445-50.
173. *Piddock L. J.* Teixobactin, the first of a new class of antibiotics discovered by iChip technology? *J Antimicrob Chemother.* 2015;70(10):2679-80.
174. *Sherpa R. T., Reese C.J., Montazeri Aliabadi H.* Application of iChip to Grow “Uncultivable” Microorganisms and its Impact on Antibiotic Discovery. *J Pharm Pharm Sci.* 2015;18(3):303-15.
175. *Ling L. L., Schneider T., Peoples A. J., Spoering A. L., Engels I., Conlon B. P., et al.* A new antibiotic kills pathogens without detectable resistance. *Nature.* 2015; 517(7535):455-9.
176. *Kaeberlein T., Lewis K., Epstein S. S.* Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. *Science.* 2002;296(5570):1127-9.

## КНИГИ

- Macfarlane, Gwyn. *Alexander Fleming.* London: Hogarth Press (Chatto & Windus); 1984.
- Lax, Eric. *The Mold In Dr. Florey’s Coat.* New York: H. Holt; 2004.
- Rosen, William. *Miracle Cure.* New York: Viking; 2017.
- Brown, Kevin. *Penicillin Man.* Sutton Publishing Limited; 2004.
- Hager, Thomas. *The Demon Under the Microscope.* Harmony; 2006.
- Martin, Barbara. *Elixir.* Barkberry Press; 2014.
- Spitz, Vivien. *Doctors From Hell.* Sentient; 2005.
- Jones, James. *Bad Blood.* Free Press; 1993.
- Stark, Laura. *Behind Closed Doors.* University of Chicago; 2012.
- Hilts, Phillip. *Protecting America’s Health.* Knopf; 2003.
- Sinclair, Upton. *The Jungle.* New York: New American Library; 1906.

На русском: Джунгли: роман / Э. Синклер ; пер. с англ. Д. М. Горфинкель и Э.Л.Линецкой ; ил. А. Васина. — Москва: Гослитиздат, 1956.

Drea, Edward. *War At The End Of The World*. CreateSpace; 2015.

Chernow, Ron. *Titan*. Vintage; 2004.

На русском: Чернов Рональд, Титан. Жизнь сэра Джона Д. Рокфеллера. — Москва: Крон-Пресс, 1999.

Blum, Deborah. *The Poison Squad*. Penguin Press; 2018.